- Miriplatin
-
- $0.00 / 1g
-
2023-11-01
- CAS:141977-79-9
- Min. Order: 1g
- Purity: 90.0% min
- Supply Ability: 100kgs/month
- Miriplatin
-
- $15.00 / 1KG
-
2021-07-13
- CAS:141977-79-9
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Miriplatin
-
- $15.00 / 1KG
-
2021-07-09
- CAS:141977-79-9
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Miriplatin Basic information |
| Product Name: | Miriplatin | | Synonyms: | [(1R,2R)-1,2-Cyclohexanediamine]bis(myristato)platinum;Miripla;SM 11355;(SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis(myristato-kappaO)platinum;(SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis(myristato-kappaO)platinum(II);(SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis...;(SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2]bis(tetradecanoato-κO)platinum;Mibo | | CAS: | 141977-79-9 | | MF: | C34H66N2O4Pt | | MW: | 762 | | EINECS: | | | Product Categories: | | | Mol File: | 141977-79-9.mol |  |
| | Miriplatin Chemical Properties |
| storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | | solubility | DMF : < 1 mg/mL (insoluble) | | form | Solid | | color | White to off-white |
| | Miriplatin Usage And Synthesis |
| Uses | Miplatin is a platinum-based anticancer drug developed by Japan's Sumitomo Pharmaceutical Co., Ltd. It is used in the treatment of liver cancer, malignant lymphoma, non-small cell lung cancer, small cell lung cancer and superficial bladder cancer. | | Biological Activity | Miriplatin (SM-11355) is a derivative of cisplatin containing myristate as a carrier ligand. It is a novel lipophilic platinum complex for the treatment of hepatocellular carcinoma. | | in vitro | Miriplatin (SM-11355) suspended in LPD (miriplatin/LPD, 100 μg/mL) inhibits the growth of AH109A cells, forms platinum-DNA adducts, and induces apoptosis. < b> | | in vivo | Miriplatin (SM-11355) (0.02-0.4 mg/20 μL) in lipiodol reduces tumor growth rates in a dose dependent manner in rats bearing AH109A tumor cells. Miriplatin/LPD (400 μg/head) significantly reduces tumor growth rates the growth of tumor in rats bearing AH109A cells. |
| | Miriplatin Preparation Products And Raw materials |
|